Description

cis-Pralsetinib Hydrochloride (cis-Blu-667 Hydrochloride) is a specific stereoisomeric form of a potent and selective RET (Rearranged during Transfection) kinase inhibitor. This high-purity pharmaceutical intermediate is critical for the research and development of targeted cancer therapies, particularly for non-small cell lung cancer (NSCLC) and other RET-altered solid tumors. It is essential for pharmaceutical manufacturers, contract research organizations (CROs), and academic institutions engaged in oncology drug discovery and API synthesis.

Application

• Active Pharmaceutical Ingredient (API) Intermediate: A key building block in the synthesis of Pralsetinib (Gavreto®).
• Oncology Research & Development: Used in preclinical and clinical studies to investigate RET-driven tumorigenesis and therapeutic efficacy.
• Reference Standard: Serves as a certified reference material (CRM) for analytical method development, validation, and quality control in pharmaceutical manufacturing.
• Process Chemistry & Scale-Up: Employed in route scouting, optimization, and pilot-scale production of RET inhibitor drug candidates.
• Mechanistic Studies: Utilized in biochemical and cellular assays to study kinase selectivity, potency, and resistance mechanisms.
• Formulation Development: A critical component in developing stable and bioavailable dosage forms for clinical trials.

Basic Information

Item	Detail
Product Name	cis-Pralsetinib Hydrochloride (cis-Blu-667 Hydrochloride)
CAS No.	2097132-93-7
Molecular Formula	C27H32F2N6O3 • HCl
Molecular Weight	554.04 g/mol (Free base: 518.58)
Synonyms	cis-BLU-667 Hydrochloride; cis-N-(4-(6,7-Dimethoxyquinolin-4-yloxy)-3-fluorophenyl)-4-fluoro-1-(2-fluoroethyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Hydrochloride; (cis)-Pralsetinib HCl; cis-1-(2-Fluoroethyl)-N-(4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)-3-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Hydrochloride; BLU-667 (cis-isomer) HCl; RET Kinase Inhibitor cis-isomer HCl
EINECS	Contact for details

Quality Control

Our cis-Pralsetinib Hydrochloride is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity and chiral assay, NMR and MS for structural confirmation, and stringent control of residual solvents and impurities in accordance with ICH guidelines. A comprehensive Certificate of Analysis (COA) is provided with every shipment, ensuring traceability and compliance with your research or cGMP requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C) or as specified on the label. This material is hygroscopic (moisture-sensitive) and must be handled under anhydrous conditions to maintain stability and potency.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (MS)	Conforms to structure
Purity (HPLC)	≥98.0% (Area Percent)
Chiral Purity (Chiral HPLC)	≥99.0% (cis-isomer)
Water Content (KF)	≤1.0%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	<20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.